SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]
We hope you are enjoying Optimum’s weekly newsletter – subscribe on LinkedIn today so you never miss an edition. Our clients Loqus23 Therapeutics and Ona Therapeutics continued the stream of good news for February with key leadership appointments. LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors LoQus23 Therapeutics Ltd, […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]
